OSTEOLYSIS TREATMENT
Methods and treatments for osteolysis employing interleukin-1 receptor antagonist (IL-1ra). Activating production of interleukin-1 receptor antagonist includes incubating adipose tissue, adipocytes, whole blood, platelet rich plasma, and/or isolated white blood cells with polyacrylamide beads to produce a solution rich in interleukin-1 receptor antagonist. Activating the production of interleukin-1 receptor antagonist includes using an implantable device loaded with adipose tissue, adipocytes, whole blood, platelet rich plasma, and/or isolated white blood cells. Methods for treating osteolysis at the site of an artificial joint in a patient include administering and/or inserting the solution rich in interleukin-1 receptor antagonist and/or the implantable device, respectively.
1 . A method for treating osteolysis due to wear debris at a site of an artificial joint implant in a patient, the method comprising administering at or proximate to the wear debris at the site of the artificial joint implant a solution rich in interleukin-1 receptor antagonist.
2 . The method according to claim 1 , wherein the interleukin-1 receptor antagonist is autologous to the patient.
3 . The method according to claim 1 , wherein the solution comprises interleukin-1 receptor antagonist at a concentration of at least about 10,000 pg/mL.
4 . The method according to claim 1 , wherein the solution comprises interleukin-1 receptor antagonist from about 30,000 pg/mL to about 110,000 pg/mL.
5 . The method according to claim 1 , wherein the administering further comprises administering fibrinogen, thrombin, and calcium with the solution rich in interleukin-1 receptor antagonist.
6 . The method according to claim 5 , wherein the administering comprises co-administering (i) a first solution comprising the interleukin-1 receptor antagonist and the fibrinogen, and (ii) a second solution comprising the thrombin and the calcium.
7 . The method according to claim 5 , wherein the thrombin is made by a process comprising:
(a) loading whole blood or plasma and a calcium solution into a blood isolation device;
(b) heating the whole blood or plasma for at least about 20 minutes, at a temperature of at least about 20° C.; and
(c) isolating the thrombin by centrifuging the heated whole blood or plasma.
8 . The method according to claim 7 , wherein the whole blood or plasma used in the process to make the thrombin is obtained from the patient.
9 . The method according to claim 1 , wherein the administering includes injecting the solution rich in interleukin-1 receptor antagonist at or proximate to the wear debris at the site of the artificial joint implant using a syringe.
10 . A method for treating osteolysis due to wear debris at a site of an artificial joint implant in a patient, the method comprising administering at or proximate to the wear debris at the site of the artificial joint implant a solution rich in interleukin-1 receptor antagonist, wherein the solution rich in interleukin-1 receptor antagonist is generated by:
a. contacting a liquid volume with polyacrylamide beads, wherein the liquid volume comprises a member selected from the group consisting of adipose tissue, adipocytes, whole blood, platelet rich plasma, white blood cells, and combinations thereof; and
b. separating at least a portion of the liquid volume from the polyacrylamide beads to obtain a solution rich in interleukin-1 receptor antagonist.
11 . The method according to claim 10 , wherein the liquid volume is obtained from the patient.
12 . The method according to claim 10 , wherein the contacting comprises incubating the liquid volume with the polyacrylamide beads for a time of from about 30 seconds to about 24 hours.
13 . The method according to claim 10 , wherein the separating comprises centrifuging the liquid volume and polyacrylamide beads to obtain a supernatant comprising the solution rich in interleukin-1 receptor antagonist.
14 . A method for treating osteolysis due to wear debris at a site of an artificial joint implant in a patient, the method comprising administering at or proximate to the wear debris at the site of the artificial joint implant an implantable device for producing interleukin-1 receptor antagonist in vivo, the implantable device comprising:
an enclosed or substantially enclosed body defining an internal space, wherein a part or all of the body comprises a first bioresorbable material; and
a second bioresorbable material within the internal space, wherein the second bioresorbable material includes an activation surface;
one or more voids within the internal space; and
a liquid volume within the one or more voids, wherein the liquid volume comprises a member selected from the group consisting of adipose tissue, adipocytes, whole blood, platelet rich plasma, white blood cells, and combinations thereof.
15 . The method according to claim 14 , wherein the liquid volume is obtained from the patient.
16 . The implantable device of claim 14 , wherein the activation surface comprises immunoglobulin G.